These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1423 related articles for article (PubMed ID: 32644110)

  • 1. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
    Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
    Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    Schneider BP; Jiang G; Ballinger TJ; Shen F; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Hancock BA; Kassem N; Helft P; O'Neil B; Storniolo AMV; Badve S; Miller KD; Radovich M
    J Clin Oncol; 2022 Feb; 40(4):345-355. PubMed ID: 34910554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
    Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
    Ortolan E; Appierto V; Silvestri M; Miceli R; Veneroni S; Folli S; Pruneri G; Vingiani A; Belfiore A; Cappelletti V; Vismara M; Dell'Angelo F; De Cecco L; Bianchi GV; de Braud FG; Daidone MG; Di Cosimo S
    ESMO Open; 2021 Apr; 6(2):100086. PubMed ID: 33743331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
    Goodman CR; Seagle BL; Friedl TWP; Rack B; Lato K; Fink V; Cristofanilli M; Donnelly ED; Janni W; Shahabi S; Strauss JB
    JAMA Oncol; 2018 Aug; 4(8):e180163. PubMed ID: 29800954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Parsons HA; Blewett T; Chu X; Sridhar S; Santos K; Xiong K; Abramson VG; Patel A; Cheng J; Brufsky A; Rhoades J; Force J; Liu R; Traina TA; Carey LA; Rimawi MF; Miller KD; Stearns V; Specht J; Falkson C; Burstein HJ; Wolff AC; Winer EP; Tayob N; Krop IE; Makrigiorgos GM; Golub TR; Mayer EL; Adalsteinsson VA
    Ann Oncol; 2023 Oct; 34(10):899-906. PubMed ID: 37597579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
    Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
    Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
    Clin Cancer Res; 2024 Jun; 30(11):2444-2451. PubMed ID: 38470545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study.
    Lee TH; Kim H; Kim YJ; Park WY; Park W; Cho WK; Kim N
    Cancer Res Treat; 2024 Apr; 56(2):531-537. PubMed ID: 37946409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
    Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of breast-conserving treatment for triple-negative breast cancer].
    Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
    Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
    ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Singareeka Raghavendra A; Liu D; Shen Y; Barcenas CH; Ueno NT; Giordano S; Tripathy D; Sri Karuturi M
    Breast Cancer Res Treat; 2024 Aug; 207(1):81-90. PubMed ID: 38916821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.